Animal and human ocular surface response to a topical nonimmune mast-cell degranulating agent (compound 48/80).

Topical application of the nonimmune selective mast-cell degranulating agent, compound 48/80, produced the signs and symptoms of ocular allergy (itching, injection, chemosis, and mucous discharge) in eight guinea pigs, eight rabbits, and nine humans. The histamine H1 receptor antagonist, antazoline phosphate, blocked itching but not vasodilation in five humans pretreated with compound 48-80. This suggests that histamine was one of the mediators released by compound 48-80-induced degranulation. Compound 48-80 may be helpful in evaluating the effects of therapeutic agents capable of modifying mast-cell degranulation and in the study of mediators involved in external ocular inflammation.
AuthorsI J Udell, M B Abelson
JournalAmerican journal of ophthalmology (Am J Ophthalmol) Vol. 91 Issue 2 Pg. 226-30 (Feb 1981) ISSN: 0002-9394 [Print] United States
PMID6162389 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • p-Methoxy-N-methylphenethylamine
  • Antazoline
  • Administration, Topical
  • Animals
  • Antazoline (pharmacology)
  • Drug Hypersensitivity (etiology)
  • Eye (drug effects)
  • Eye Diseases (chemically induced)
  • Guinea Pigs
  • Histamine Release (drug effects)
  • Humans
  • Male
  • Mast Cells (drug effects)
  • Rabbits
  • p-Methoxy-N-methylphenethylamine (adverse effects, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: